Sage shakes up leadership, appoints ex AZ and Shire staff
This article was originally published in Scrip
Executive Summary
Biopharmaceutical firm Sage Therapeutics, which develops products to treat CNS disorders and orphan diseases, has appointed Dr Jeffery Jonas chief executive officer. He succeeds Kevin Starr who has been interim CEO since the company's founding in 2011. Prior to joining the Cambridge, Massachusetts-based firm Dr Jonas was president of regenerative medicine at Dublin, Ireland-headquartered biopharmaceutical firm Shire.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.